Signifor: new treatment for Cushing's disease

Signifor is the first targeted treatment for Cushing's disease, an endocrine disorder caused by excessive cortisol production resulting from an underlying pituitary tumour.

The recommended starting dose of Signifor is 600 microgram by subcutaneous injection twice daily.
The recommended starting dose of Signifor is 600 microgram by subcutaneous injection twice daily.

PHARMACOLOGY

Pasireotide is a novel cyclohexapeptide somatostatin analogue. It binds with high affinity to four of the five somatostatin receptor subtypes.1 Activation of these receptors on ACTH-secreting pituitary tumours inhibits the excessive production of ACTH that leads to the symptoms of Cushing’s disease.

CLINICAL STUDIES

The efficacy and safety of pasireotide in the treatment of Cushing’s disease were assessed in a randomised, double-blind phase III trial (n=162), involving adult patients with urinary-free cortisol (UFC) levels at least 1.5 times the upper limit of normal.2 Pasireotide was administered by subcutaneous injection twice daily. The primary endpoint was normalisation of UFC at six months, defined as a level at or below the upper limit of normal, with no prior dose increase.

After six months, mean UFC levels had normalised in 14.6% (95% CI 7.0–22.3) of patients receiving pasireotide 600 microgram twice daily and in 26.3% (95% CI 16.6–35.9) of those receiving 900 microgram twice daily. The primary endpoint was therefore determined to have been met in the 900 microgram group.1,2

Decreases in blood pressure, BMI and total cholesterol were observed at six months in patients with both full and partial mean UFC control.1

Pasireotide was associated with hyperglycaemia-related adverse events in 73% of patients; other adverse effects were similar to those observed with other somatostatin analogues.2

Novartis is currently undertaking a phase III trial to evaluate a longer-acting form of pasireotide that only requires injection once a month.

References:

1.    Signifor Summary of Product Characteristics, April 2012.
2.    Colao A et al. N Engl J Med 2012; 366: 914-24.

View Signifor drug record

Further information: Novartis

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

FemSeven Conti back in stock

FemSeven Conti back in stock

FemSeven Conti (estradiol/levonorgestrel) HRT patches...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Trial of interferon beta in COVID-19 patients begins in UK

Trial of interferon beta in COVID-19 patients begins in UK

A global phase III clinical trial to evaluate an inhaled...